From: Microglial activation in Parkinson’s disease using [18F]-FEPPA
Total (n = 52) | HC (n = 22) | PD (n = 30) | |
---|---|---|---|
Age, mean (SD) | 65.0 (7.70) | 64.4 (8.06) | 65.5 (7.54) |
Gender (M:F) | 33:19 | 11:11 | 22:8 |
TSPO genotype | 27 HAB, 25 MAB | 11 HAB, 11 MAB | 16 HAB, 14 MAB |
Handedness (R:L:both) | 38:5:1 | 13:0:1 | 25:5:0 |
Years of education, mean (SD) | 16.4 (3.25) | 16.3 (3.00) | 16.4 (3.40) |
MoCA, median (range) | 28 (26–30) | 28 (26–30) | 28 (26–30) |
MMSE, median (range) | 29.5 (27–30) | ||
BDI II, median (range) | 6 (0–23) | 4.5 (0–16) | 8 (0–23) |
Symptom dominant side (R:L) | 19:11 | ||
UPDRS III, median (range) | 24 (4–45) | ||
Duration of disease (years), median (range) | 5 (2–15) | ||
Total LEDD, mean (SD) | 395.5 (483.21) | ||
Amount injected (mCi), mean (SD) | 4.9 (0.28) | 4.8 (0.22) | 5.0 (0.27)a |
Mass injected (μg), mean (SD) | 1.0 (0.70) | 1.1 (0.83) | 1.0 (0.59) |
Specific radioactivity (mCi/μmol), mean (SD) | 2670.8 (1559.56) | 2707.8 (1626.74) | 2643.6 (1536.00) |